![Sanne Weijzen](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Profil
Sanne is a partner at Aglaia.
She draws her experience from a scientific career covering multiple research areas.
This is supplemented by knowledge in and experience with IP management and strategy.
Anciens postes connus de Sanne Weijzen
| Sociétés | Poste | Fin |
|---|---|---|
Aglaia Management BV
 Aglaia Management BV Investment ManagersFinance Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America. They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems. Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing. | Private Equity Investor | 01/09/2014 |
Aglaia Management BV
Aglaia Management BV Investment ManagersFinance Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America. They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems. Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing. | Private Equity Investor | 01/03/2011 |
Aglaia Management BV
Aglaia Management BV Investment ManagersFinance Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America. They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems. Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing. | Analyste en capital-investissement | 01/04/2009 |
InteRNA Technologies BV
 InteRNA Technologies BV BiotechnologyHealth Technology Engages in the development of novel breakthrough therapies in chronic disorders | Directeur/Membre du Conseil | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
2
Relations au 1er degré
2
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 2 |
|---|---|
Aglaia Management BV
Aglaia Management BV Investment ManagersFinance Aglaia's investment strategy focuses on seed and early-stage biomedical ventures exclusively in oncology. They invest primarily in preclinical and early-clinical development opportunities from research institutes based in The Netherlands. They also consider transactions with biomedical partners in Europe and in North America. They seek to invest in new tools and techniques in addition to components of contemporary drug development, such as production and selection systems for biomedical products, vehicles for drug delivery and drug targeting, diagnostic tools and essays, micro-array applications, screening assays, drug targets, drugs and drug systems. Aglaia is an active investment partner in driving product development. In addition to providing capital, they draw on their biomedical industry network and knowledge. They identify trends and formulate operating strategies. They seek to bring on board new investors and may also participate themselves in subsequent rounds of financing. | Finance |
InteRNA Technologies BV
InteRNA Technologies BV BiotechnologyHealth Technology Engages in the development of novel breakthrough therapies in chronic disorders | Health Technology |
Choisissez Zonebourse 
